Suseong Salvacion "Discussing 'Kovixil' Supply with Multiple Middle Eastern Pharmaceutical Companies in Preparation for MERS"

[Asia Economy Reporter Jang Hyowon] Suseong Salvacion announced on the 10th that it is discussing the supply of Kobixil with multiple local pharmaceutical companies in the Middle East through its affiliate Salvacion.

According to the company, this is expected to be in preparation for the MERS virus during the ‘Hajj,’ one of the five pillars of Islam, which will be held in July. In the 2019 Hajj, 2.5 million people from around the world attended.

The MERS virus (Middle East Respiratory Syndrome Coronavirus) was first discovered in 2012 and arrived in Korea in 2015. In the early stages, MERS was known as a virus more frightening than Ebola, which has a maximum fatality rate of 90%. The Middle East region experiences periodic outbreaks of MERS, and health authorities are working to prevent its spread by urging travelers to be cautious.

A company official said, “MERS belongs to the coronavirus family, similar to COVID-19, and infections are still occurring worldwide,” adding, “There is a persistent risk of co-infection with COVID-19, and the probability of severe symptoms increases if co-infection occurs.”

He continued, “Currently, there is no clear vaccine or treatment, so prevention and isolation are the best measures,” and added, “Last month, five children arriving on a passenger plane from the UAE (United Arab Emirates) showed respiratory symptoms, prompting health authorities to conduct tests for MERS and COVID-19.”

A company representative stated, “Thanks to the government’s eco-friendly policies, sales growth in our core business of electric In-Building logistics equipment is remarkable, and inquiries from overseas are increasing,” adding, “Along with this, sales growth of Kobixil in the new business division continues, making a performance turnaround certain this year.”

He added, “We are currently discussing the supply of approximately 3 million units of Kobixil with Middle Eastern pharmaceutical companies.”